Netflix will be saying au revoir to Emily in Paris — one of the streamer’s most popular shows — with its sixth season, the series’ creator has announced. The show, which stars Lily Collins as the ...

Delar av Stockholms central utrymdes under morgonen efter ett automatlarm utlösts. Larmet om branden kom 08.30 och ska ha ...

Delar av Stockholms central är på väg att utrymmas då ett automatlarm utlösts. Vare sig polis eller räddningstjänst kan i ...

Of course, Lilly isn't alone in this market -- it shares the space with Novo Nordisk, seller of blockbuster drugs Ozempic and Wegovy. And Lilly also faces the possibility of more competition down the ...

Terence Flynn, an analyst at Morgan Stanley, recently reiterated an overweight (or "buy") rating on Eli Lilly stock along with a price target of $1,327. That suggests an upside of about 52% from its ...

I fyran öser William Pihl från Waggeryd in mål och Theodor Curmark har gjort hela tio mål för sitt Tenhult så här långt.

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too. Lilly notified Rigel ...

Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline. Lilly has been ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Eli Lilly’s latest attempt to strengthen its genetic medicine offering has seen the Big Pharma team up with Profluent to develop AI-designed recombinases to address diseases with severe unmet needs.

LAS VEGAS -- Vegas Golden Knights center William Karlsson returned on Monday night, in his club's 3-1 win over the Anaheim Ducks, after missing nearly six months with a lower-body injury. After ...

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...